Abstract
A 73-year-old female with hepatocellular carcinoma (HCC) received percutaneous transhepatic portal vein embolization (PTPE) before extensive right lobe hepatectomy. Serum levels of des-gamma-carboxy-prothrombin (DCP) were increased and remained at a high level until hepatectomy. Immunohistochemical examination revealed that an increased expression of DCP was demonstrated not only in HCC tissues, but also in the non-cancerous liver of the right lobe, where portal blood flow was blocked off as a result of PTPE. The serum level of DCP is known to be greatly increased in patients with HCC accompanied by portal vein invasion. We speculate that this increased DCP level is caused by both increased DCP production in HCC tissue and the surrounding non-cancerous liver, where portal flow is blocked off as a result of portal invasion by HCC.
Similar content being viewed by others
References
Zhu R, Yang J, Xu L, et al. Diagnostic performance of des-gamma-carboxy prothrombin for hepatocellular carcinoma: a meta-analysis. Gastroenterol Res Pract. 2014;2014:529314.
Gao P, Li M, Tian QB, Liu DW. Diagnostic performance of des-gamma-carboxy prothrombin (DCP) for hepatocellular carcinoma: a bivariate meta-analysis. Neoplasma. 2012;59:150–9.
Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502.
Lamerz R, Runge M, Stieber P, Meissner E. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res. 1999;19:2489–93.
Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–9.
Nakao A, Suzuki Y, Isshiki K, et al. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroenterol. 1991;86:62–6.
Kato A, Yasuda H, Togawa A, et al. Measurement of des-gamma-carboxy prothrombin levels in hemodialysis patients positive for anti-hepatitis virus C antibody. Clin Nephrol. 2002;58:296–300.
Tamano M, Sugaya H, Oguma M, et al. Immunolocalisation of PIVKA-II in paraffin-embedded specimens of hepatocellular carcinoma. Liver. 1999;19:406–10.
Murata K, Suzuki H, Okano H, et al. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2010;36:161–70.
Yuan LW, Tang W, Kokudo N, et al. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma. Oncol Rep. 2004;12:269–73.
Xiang CH, Zhang W, Inagaki Y, et al. Measurement of serum and tissue des-gamma-carboxyprothrombin in resectable hepatocellular carcinoma. Anticancer Res. 2008;28:2219–24.
Tang W, Kokudo N, Sugawara Y, et al. Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep. 2005;13:25–30.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest:
Tetsuro Sohda, Kaoru Iwata, Akira Anan, Hideo Kunimoto, Kaoru Yotsumoto, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Akinobu Osame, Shinichi Kora, Jun Ohishi, Yasushi Yamauchi, Tomoaki Noritomi, Kengo Yoshimitsu, Yuichi Yamashita, and Shotaro Sakisaka declare that they have no conflict of interest.
Human/Animal Rights:
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).
Informed Consent:
Informed consent was obtained from all patients for being included in the study.
Rights and permissions
About this article
Cite this article
Sohda, T., Iwata, K., Anan, A. et al. Upregulation of des-gamma-carboxy-prothrombin after portal vein embolization in a cirrhotic patient with hepatocellular carcinoma. Clin J Gastroenterol 8, 330–334 (2015). https://doi.org/10.1007/s12328-015-0603-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-015-0603-x